Welcome to our dedicated page for Puretech Health SEC filings (Ticker: PRTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The PureTech Health plc (PRTC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq and the London Stock Exchange. PureTech files under Form 20-F and uses Form 6-K to furnish current reports, press releases, financial information, and other updates under the U.S. Securities Exchange Act of 1934.
Recent Form 6-K filings referenced in company communications include current reports related to leadership transitions, the appointment of a Chief Executive Officer, and the publication of half-year results with interim management reports and unaudited condensed consolidated financial statements. These filings give investors detail on PureTech’s hub-and-spoke biotherapeutics model, portfolio composition, capital allocation priorities, and financial position, including its description of PureTech-level cash and operational runway.
For a company like PureTech, SEC filings are a key source for understanding how its core programs and Founded Entities are reflected in consolidated reporting, how it describes risks and uncertainties, and how it presents its capital-efficient R&D strategy to regulators and investors. Filings can also incorporate press releases that discuss clinical progress for programs such as deupirfenidone (LYT-100) in idiopathic pulmonary fibrosis, LYT-200 in acute myeloid leukemia, and Glyph-based candidates at Seaport Therapeutics.
On Stock Titan, users can review PureTech’s 6-K submissions as they are furnished to EDGAR, alongside annual reporting on Form 20-F when available. The platform is designed to make it easier to follow new filings in real time and to pair them with AI-powered summaries that explain the context and main points of lengthy documents, helping readers quickly understand how each filing relates to PureTech’s broader strategy and portfolio.
PureTech Health plc reported a leadership change, announcing that Robert Lyne has been appointed as its Chief Executive Officer. This update comes through a Form 6-K submission that notes the company issued a press release titled “PureTech Appoints Robert Lyne as Chief Executive Officer” on December 18, 2025. The press release is furnished as Exhibit 99.1 and incorporated by reference, indicating it contains further details about Lyne’s new role and the company’s leadership plans.
PureTech Health plc submitted a Form 6-K as a foreign private issuer to provide investors with its half-year information package. The company furnished a press release summarizing its half-year report, an interim management report and financial review for the six months ended June 30, 2025 and 2024, and unaudited condensed consolidated financial statements covering the same periods and as of December 31, 2024. These materials give a detailed update on the company’s mid-year performance and financial position, but the specific financial results are contained in the attached exhibits rather than in this cover document.
Citigroup and several of its subsidiaries report a collective beneficial ownership of 13,220,374 ordinary shares of PureTech Health plc, representing 5.5% of the class. The filing names five Citigroup reporting persons and discloses that the position carries shared voting power and shared dispositive power; no sole voting or dispositive authority is reported.
The statement indicates the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. The filing also describes the chain of ownership among the Citigroup entities that hold the position.